

Extraordinary Report

March 27, 2026

(TRANSLATION)

Note for readers of this English translation

On March 27, 2026, Chugai Pharmaceutical Co., Ltd. filed its Japanese-language Extraordinary Report (*Rinji Houkokusho*) with the Director-General of the Kanto Financial Bureau in Japan in connection with the Company's shareholders' voting results for proposals acted upon at the 115th Annual General Meeting of Shareholders held on March 26 2026, pursuant to the Financial Instruments and Exchange Act of Japan. This document is an English translation of the Report.

1. Reason for submitting the Extraordinary Report

Given that resolutions were made for the proposals at the 115th Annual General Meeting of Shareholders (the "Meeting") held on March 26, 2026, Chugai Pharmaceutical Co., Ltd. (the "Company") submits this Extraordinary Report under the provisions of Article 24-5, Paragraph 4, of the Financial Instruments and Exchange Act of Japan and Article 19, Paragraph 2, Item 9-2, of the Cabinet Office Ordinance on Disclosure of Corporate Information, etc. (the "Report").

2. Contents of the Report

(1) Date when the Meeting was held; March 26, 2026

(2) Matters for resolution

First Proposal: Appropriation of Surplus

Year-end dividend

JPY 147 per share of common stock of the Company

Second Proposal: Election of Nine (9) Directors

Elect Osamu Okuda, Iwaaki Taniguchi, Hitoshi, Fumio Tateishi, Hideo Teramoto, Kinuko Mitani, Thomas Schinecker, Teresa A. Graham and Boris L. Zaïtra as Directors of the Company.

Third Proposal: Revision of Stock Compensation System for Directors

Revision to Trust-Based Stock Compensation System for Directors (excluding Non-Executive Directors) in place of the restricted stock compensation. The maximum amount of money to be contributed by the Company to the Trust shall be JPY 450 million per fiscal year, and the maximum number of the Company's shares to be delivered to Directors shall be 150,000 shares per fiscal year.

(3) Number of voting rights concerning the indication of "for", "against" or "abstention" for each proposal; and Requirements for approving the proposals: Results of the resolutions

Proposal	For	Against	Abstention	Ratio of favorable votes	Results
First Proposal	15,046,460	20,998	959	99.85%	Approved
Second Proposal					
Osamu Okuda	11,730,887	3,311,486	26,014	77.85%	Approved
Iwaaki Taniguchi	14,477,943	562,352	28,119	96.08%	Approved
Hitoshi Iikura	14,480,030	560,264	28,119	96.09%	Approved
Fumio Tateishi	14,560,076	507,382	959	96.63%	Approved
Hideo Teramoto	14,579,923	487,536	959	96.76%	Approved
Kinuko Mitani	14,787,633	279,829	959	98.14%	Approved
Thomas Schinecker	14,478,968	561,326	28,119	96.09%	Approved
Teresa A. Graham	14,487,208	553,086	28,119	96.14%	Approved
Boris L. Zaïtra	14,262,207	778,077	28,119	94.65%	Approved
Third Proposal	15,009,113	58,340	959	99.61%	Approved

Notes: Requirements for the approval of each proposal are as follows:

- 1) The resolution for the First and Third Proposals must be adopted by the majority of the votes of the shareholders present who are entitled to exercise their voting rights.
- 2) The resolution for the Second Proposal must be adopted by a majority of the votes of the shareholders present at the Meeting where the number of the voting rights of the shareholders present, amounts to one-third (1/3) or more.

(4) Reason why a portion of the voting rights held by the shareholders present at the Meeting held on March 26, 2026, was not added to the number of voting rights

Because in terms of Japanese Companies Act, the required majority approval for each proposal was met by the votes exercised prior to the Meeting held on March 26, 2026, as well as the votes exercised by a portion of shareholders present and confirmed by the Company at the Meeting held on March 26, 2026; and the voting rights of the shareholders present at the Meeting held on March 26, 2026, untraceable with the final decision of "for", "against" or "abstention" as to each proposal were not tallied.